What is Disc Medicine's SG&A?

Disc Medicine (IRON) reported SG&A of $23.62M in Q1 2026.

How has Disc Medicine's SG&A changed year-over-year?

Disc Medicine's SG&A increased by 93.9% year-over-year, from $12.18M to $23.62M.

What is the long-term trend for Disc Medicine's SG&A?

Over 2 years (2023 to 2025), Disc Medicine's SG&A has grown at a 72.9% compound annual growth rate (CAGR), from $21.86M to $65.38M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Disc Medicine IRON SG&A

SG&A at other companies

Bristol-Myers SquibbBMY

$1.62B+2.1%

Vertex PharmaceuticalsVRTX

$493.7M+24.5%

Agios PharmaceuticalsAGIO

$48.3M+16.3%

Travere Therapeutics, Inc.TVTX

$80.25M+32.8%

BridgeBio PharmaBBIO

$163.9M+54.1%

PTC TherapeuticsPTCT

$86.18M+6.5%

Other financials

Income statement

See full

Operating income-$69.5M-74.0%

Net income-$63.5M-86.3%

EPS (diluted)-$1.65-61.8%

Balance sheet

See full

Cash & equivalents$88.9M-27.5%

Total debt$31.1M+1.4%

Total equity$688.4M+4.3%

Total assets$750.2M+5.8%

Cash flow

See full

Operating cash flow-$62.2M-50.4%

CapEx--100%

Free cash flow-$62.2M-47.4%

Valuation

See full

Market cap$2.69B+42.2%

Enterprise value$2.63B+46.7%

Returns & leverage

See full

Return on equity-35.8%+41.3pp

Debt / equity0×0.0×

Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Disc Medicine's SG&A?: Disc Medicine (IRON) reported SG&A of $23.62M in Q1 2026.
How has Disc Medicine's SG&A changed year-over-year?: Disc Medicine's SG&A increased by 93.9% year-over-year, from $12.18M to $23.62M.
What is the long-term trend for Disc Medicine's SG&A?: Over 2 years (2023 to 2025), Disc Medicine's SG&A has grown at a 72.9% compound annual growth rate (CAGR), from $21.86M to $65.38M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.